Remus Pharmaceuticals IPO – Review, Bid, Size, Allotment, Subscription, GMP & RHP
Last Updated Date: May 19, 2023Let’s have a detailed review of the company and analytics of the Remus Pharmaceuticals IPO release date, IPO offer price, subscription, Remus Pharmaceuticals Limited IPO allotment, grey market price, and other details like the company’s background, its financial positions, its promoters, and other related things.
| Face Value | Rs 10 |
| Price Band | Rs 1150 to Rs 1229 |
| Listing At | NSE, SME |
| Min. Order Quantity | 100 Shares |
| Listing Date | 29 May 2023 |
| Offer for Sale | Rs Lakh |
| Fresh Issue | Rs 4,769 Lakh |
| IPO Size | Rs 4,769 Lakh |
| Tick Size | 1 |
Remus Pharmaceuticals IPO is listed at a [●] premium. Check out the live share price by clicking on the below link.
| Live Performance – Remus Pharmaceuticals Share Price |
Remus Pharmaceuticals IPO – Summary
Their Company was originally incorporated as ‘Remus Pharmaceuticals Private Limited’ as a private limited company, under the provisions of the Companies Act, 2013 vide Certificate of Incorporation dated September 21, 2015.
It is issued by the Assistant Registrar of Companies, Gujarat. Later on, pursuant to a special resolution passed by their shareholders in the Extra-Ordinary General Meeting held on January 02, 2023.
The Promoter of this company is MR. ARPIT DEEPAKKUMAR SHAH, MS. ROMA VINODBHAI SHAH, MR. SWAPNIL JATINBHAI SHAH AND MRS. ANAR SWAPNIL SHAH. The lead manager of the issue is BEELINE CAPITAL ADVISORS PRIVATE LIMITED, and the Registrar of this issue is LINK INTIME INDIA PRIVATE LIMITED.
Remus Pharmaceuticals IPO Date
The opening and closing dates of Remus Pharmaceuticals IPO are 17 May 2023 and 19 May 2023 respectively.
Remus Pharmaceuticals IPO Subscription
| Day / Date | QIB | NII | RII | Total Subscription |
| 1st Day – 17th May | 0.00x | 2.85x | 2.85x | 1.43x |
| 2nd Day – 18th May | 1.48x | 12.25x | 10.93x | 6.41x |
| 3rd Day – 19th May | 10.75x | 229.31x | 49.81x | 57.21x |
| Shares Offered or Net Issue | 138,750 | 41,625 | 97,125 | 277,500 |
The shares subscribed by the public will be updated here.
Remus Pharmaceuticals IPO Allotment Status
Here, you can find the Allotment Status of this IPO.
Allotment of Equity Shares are pursuant to the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders pursuant to the Offer for Sale to the successful Bidders. However, the Allotment Status is not yet disclosed.
Remus Pharmaceuticals Limited IPO Listing Date
Find the dates below on the basis of allotment, refund, listing, and more:
| Basis of Allotment Finalization | 24 May 2023 |
| Refunds Initiation | 25 May 2023 |
| Credit of Shares to Demat Account | 26 May 2023 |
| Share Listing Date | 29 May 2023 |
Remus Pharmaceuticals IPO Price Band
The face value of each share is Rs.10, but the price band of the IPO is Rs 1150 to Rs 1229
Remus Pharmaceuticals IPO Equity Size
This Initial Public Issue of 388,000 Equity Shares of Rs.10 each for cash at a price of Rs 1150 to Rs 1229 per equity share aggregating to Rs.4,769 Lakh.
Remus Pharmaceuticals IPO Share Offering
Fresh Issue: The Issue (excluding the Market Maker Reservation Portion) of 388,000 Equity Shares of Rs.10/ each.
Issue Size: 388,000 Equity Shares of Rs.10 each, aggregating to Rs.4,769 Lakh
Open Free Demat Account Now!
Remus Pharmaceuticals IPO – Live Performance
The listing date of this IPO is 29 May 2023. You can check the live performance of the IPO here, only after it is listed on exchanges.
| Live IPO Performance – Remus Pharmaceuticals Share Price |
Remus Pharmaceuticals IPO Grey Market Premium
The Remus Pharmaceuticals Limited IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is Rs X.
Remus Pharmaceuticals IPO – Company Overview
Their company is engaged in the marketing & distribution of finished formulations of pharmaceutical drugs. Their company also deals in API (Active Pharmaceutical Ingredient).
They also provide technical consultancy services to various distributors for the preparation of reports on the dossiers of the products to be registered by them in various countries.
Having cultivated strong and dependable customer relationships ranging from Generic distributors, regional distributors and Multinational distributors to Hospitals and Clinics through a responsive distribution network, their clients are spread in more than 20 countries.
They look forward to forming long-lasting relationships that enhance the lives of their patients. Their Company is majorly engrossed in the pharmaceutical business involving marketing, trading and distribution of a wide range of pharmaceutical finished formulations and products, manufactured under loan license and/or contract manufacturing.
Remus Pharmaceuticals IPO – Financial Statements
A quick look into the past financial performance of the company to understand its performance of the business and evaluate the growth prospectus:
Financial Summary:
| Amount (in INR & Lakh) | ||||
| 31-Dec-22 | 31-Mar-22 | Mar-21 | 31-Mar-20 | |
| Total Assets | 3,352.96 | 1,590.93 | 1,104.96 | 530.36 |
| *Total Revenue | 3,361.19 | 2,543.71 | 1,922.45 | 1,276.89 |
| Total Expense | 2,491.86 | 2,088.84 | 1,786.64 | 1,167.49 |
| Profit After Tax | 643.89 | 338.57 | 102.58 | 81.16 |
Earnings per Equity Share (in Lakh)
| 31-Dec-22 | 31-Mar-22 | Mar-21 | 31-Mar-20 | |
| Basic & Diluted | 64.35 | 33.86 | 10.26 | 8.12 |
Further, their PAT for the period ended on Dec 31, 2022, March 31, 2022, March 31, 2021, and March 31, 2020, were Rs. 643.89 Lakh, Rs. 338.57 Lakh, Rs. 102.58 Lakh and Rs. 81.16 Lakh respectively.
Remus Pharmaceuticals IPO – Promoters
The Promoter of this company is:
- ARPIT DEEPAKKUMAR SHAH,
- ROMA VINODBHAI SHAH,
- SWAPNIL JATINBHAI SHAH
- ANAR SWAPNIL SHAH
List of Related Parties (Key Managerial Personnel)
- Arpit Deepak Kumar Shah – Managing Director
- Swapnil Jatinbhai Shah – Chairman and Whole Time Director
- Roma Vinodbhai Shah – Whole Time Director
- Anar Swapnil Shah – Whole Time Director
- Balwant Purohit – Independent Director
- Sanjana Sanjeev Shah – Independent Director
- Vishrut Chandramauli Pathak – Independent Director
Remus Pharmaceuticals IPO – Promoters Holding
- Pre-Issue Share Holding – %
- Post-Issue Share Holding – %
Remus Pharmaceuticals IPO Offer Details or Issue Details
| Particulars | No. Of Equity Shares |
| Equity Shares Offered | Up to X Equity Shares aggregating up to Rs.[●] Lakh |
| of which: | |
| Issue Reserved for the Market Makers | Up to [●] Equity Shares aggregating up to Rs.[●] Lakh |
| Net Issue to the Public | Up to [●] Equity Shares aggregating up to Rs.[●] Lakh |
| Of which: | |
| Retail Investors Portion | Not less than [●] Equity Shares |
| Other than Retail Individual Investors | Not more than [●] Equity Shares |
| Equity Shares outstanding prior to the Issue | X Equity Shares |
| Equity Shares outstanding after the Issue | X Equity Shares |
Remus Pharmaceuticals IPO Issue Object
Their Company proposes to utilize the Net Proceeds towards funding the following objects:
- To Meet Working Capital Requirements
- Funding investments for acquisitions and general corporate purposes
- To meet Public Issue Expenses
Remus Pharmaceuticals IPO – Business Strategy
- Improve global presence
- Leveraging their market skills and relationship
- To increase brand visibility
- Maintaining an edge over competitors
- Customer Satisfaction
Remus Pharmaceuticals IPO – Basis of Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- Experienced Promoters and Management Team
- Wide range of Products
- Strategic Location of Contract Manufacturing Facilities
- Diversified business operations and revenue base
- Scalable Business Model
The relevant quantitative factors are:
| Basic & Diluted EPS | RONW (%) | NAV (Rs.) | |
| 31-Mar-22 | 33.86 | 52.64 | 64.32 |
| 31-Mar-21 | 10.26 | 33.68 | – |
| Mar-20 | 8.12 | 40.17 | – |
Remus Pharmaceuticals IPO: Competitive Peers
| Face Value (Rs.) | P/E | EPS (Rs.) | Return on Net Worth (%) | Revenue from Operation (Rs. in Lakhs) | |
| Remus Pharmaceuticals Limited | 10 | [●] | 33.86 | 52.64 | 2471.71 |
| Listed Peers | |||||
| Trident Lifeline Limited | 10 | 21.46 | 6.92 | 82.66 | 2176.80 |
| Vaishali Pharma Limited | 10 | 42.68 | 3.82 | 15.27 | 7153.68 |
| Chandra Bhagat Pharma Limited | 10 | 99.06 | 1.06 | 2.99 | 9407.56 |
Remus Pharmaceuticals IPO Lead Managers
| Lead Managers |
| BEELINE CAPITAL ADVISORS PRIVATE LIMITED SEBI Registration Number: INM000012917 Address: 807, Phoenix, Opp. Girish Cold Drinks, Near Vijay Cross Roads, Navrangpura, Ahmedabad -380009, Gujarat. Telephone Number: 079 4840 5357 Email Id: mb@beelinemb.com Investors Grievance Id: ig@beelinemb.com Website: www.beelinemb.com Contact Person: Mr. Nikhil Shah CIN: U67190GJ2020PTC114322 |
Remus Pharmaceuticals IPO Registrar to offer
| Registrar to the Offer |
| LINK INTIME INDIA PRIVATE LIMITED SEBI Registration Number: INR000004058 Address: C-101, 1st Floor, 247 Park, Lal Bahadur Shastri Marg, Vikhroli (West), Mumbai, Maharashtra, India – 400 083. Tel. Number: +91 810 811 4949 Fax- +91 22 4918 6195 Email Id: remuspharmaceuticals.ipo@linkintime.co.in Investors Grievance Id: remuspharmaceuticals.ipo@linkintime.co.in Website: www.linkintime.co.in Contact Person: Shanti Goapalkrishnan CIN: U67190MH1999PTC118368 |
Remus Pharmaceuticals IPO – Other Details
- Statutory Auditor – M/s. Parikh & Majmudar, Chartered Accountants
- Legal Counsel to the Company – M V KINI, LAW FIRM
- Bankers to the Company – ICICI Bank Limited
Remus Pharmaceuticals IPO Review by Stock Brokers
| Top Stock Brokers Review | Company Reputation | Competitive Edge | Financial Statement | Popularity Index | Promoters Reputation |
| Angel Broking | 7.5/10 | 7.4/10 | 8.5/10 | 8.1/10 | 7.1/10 |
| Sharekhan | 7.2/10 | 7.1/10 | 8.6/10 | 8.1/10 | 7.2/10 |
| Kotak Securities | 7.3/10 | 7.5/10 | 8.4/10 | 8.1/10 | 7.3/10 |
| ICICI Direct | 7.3/10 | 7.3/10 | 8.7/10 | 8.1/10 | 7.1/10 |
| IIFL | 7.5/10 | 7.2/10 | 8.8/10 | 8.0/10 | 7.1/10 |
| Edelweiss | 7.5/10 | 7.4/10 | 8.4/10 | 8.3/10 | 7.2/10 |
| Zerodha | 7.4/10 | 7.1/10 | 8.5/10 | 8.1/10 | 7.0/10 |
| 5Paisa | 7.1/10 | 7.1/10 | 8.4/10 | 8.1/10 | 7.1/10 |
| Karvy | 7.4/10 | 7.3/10 | 8.2/10 | 8.1/10 | 7.1/10 |
| Motilal Oswal | 7.1/10 | 7.1/10 | 8.6/10 | 8.3/10 | 7.2/10 |
Subscribe to Remus Pharmaceuticals IPO
Remus Pharmaceuticals Limited IPO News
News 1 – IPO DRHP Download
News 2 – IPO RHP Prospectus Download
Remus Pharmaceuticals IPO Review FAQs
Check out various FAQs related to Remus Pharmaceuticals IPO:
What is the Issue Size of Remus Pharmaceuticals IPO?
The Company is making an initial public offer of 388,000 equity shares. They vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.
What is the Price band of Remus Pharmaceuticals IPO?
The price band for this particular IPO ranges between Rs 1150 to Rs 1229. As far as the face value of the share is of concern, it is Rs. 10 per share.
What is the Remus Pharmaceuticals IPO Open Date?
The opening and closing dates for this IPO have been updated. The IPO is set to open on 17 May 2023, while the closing date is set for 19 May 2023.
What is the Remus Pharmaceuticals IPO Allotment Date?
They also have the news regarding the respective allotment dates of this IPO. The basis of Allotment finalization is on 24 May 2023, refund initiation is on 25 May 2023, credit of shares is on 26 May 2023, and share listing date is on 29 May 2023.
What is the Remus Pharmaceuticals IPO Listing Date?
Shares of this company shall be listed in the exchanges on 29 May 2023. The date, when the listing would be done, is stagnant on 29 May 2023.
Who is the Registrar of Remus Pharmaceuticals IPO?
One of the reputed registrars is managing the issue of this IPO, i.e. LINK INTIME INDIA PRIVATE LIMITED. Their website will help you regarding the further information you are on the lookout for.
Who is the Promoter of Remus Pharmaceuticals IPO?
Here are the promoters of this IPO – MR. ARPIT DEEPAKKUMAR SHAH, MS. ROMA VINODBHAI SHAH, MR. SWAPNIL JATINBHAI SHAH AND MRS. ANAR SWAPNIL SHAH. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.
What is the GMP of Remus Pharmaceuticals IPO?
They have obtained the GMP of this IPO and it is Rs NA. Further insights into the Kostak rate and subject to sauda or SS are as well included in this report.
Is Remus Pharmaceuticals IPO Good for Investment?
They have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.
What is the PAT of Remus Pharmaceuticals Company?
They have the information on company financials, and according to that, they have the figures from the last few years to provide. PAT for the financial year 2022 in Lakh is 338.57, 2021 is 102.58, and 2020 is 81.16. PAT from Dec 2022 is 643.89.
Calculate your return on investment!
Asset Class
ROI (Rs.)
Profit (Rs.)
Profit (%)
IPO
Equity
Savings
Real Estate
Gold
Bonds
Fixed Deposit
Mutual Fund
Featured Topics